期刊语言：英语

出版地区：美国

万维提示

1、投稿方式：在线投稿。

2、期刊网址：

https://www.thelancet.com/journals/lanonc/home

https://www.journals.elsevier.com/the-lancet-oncology/

3、投稿网址：

https://www.editorialmanager.com/thelancetoncology

4、官网邮箱：david.collingridge@lancet.com

5、官网电话：+44 [0] 20 7424 4950

6、期刊刊期：月刊，一年出版十二期。

2021年5月21日星期五

投稿须知【官网信息】

Information for Authors

The Lancet Oncology publishes interesting and informative reviews on any topic connected with oncology, and considers any original research contribution that advocates change in, or illuminates, oncological clinical practice. Manuscripts must be solely the work of the author(s) stated, must not have been previously published elsewhere, and must not be under consideration by another journal. All papers should be written to be clearly understandable to the journal’s readers in a wide range of specialties and countries.

The journal publishes a range of article types that encompass all aspects of oncological medicine: Comment, Correspondence, News, Perspectives, Article, Review, Policy Review, and Personal View.

All original research judged eligible for consideration by the journal’s editors will be peer-reviewed within 72 h and, if accepted, published within 8 weeks from submission. All accepted Articles will be published online first before appearing in the print journal. The Lancet is a signatory journal to the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, issued by the International Committee of Medical Journal Editors (ICMJE Recommendations), and to the Committee on Publication Ethics (COPE) code of conduct for editors. We follow COPE’s guidelines.

If your question is not addressed on these pages then please email the Editor at david.collingridge@lancet.com.

Submissions to The Lancet Oncology should include:

1 Covering letter

2 Manuscript including tables and panels

3 Figures

4 Author statement form (see next section)

5 Declaration of interests and source of funding statements (see next section)

6 In-press papers—one copy of each with acceptance letters

7 Protocols and CONSORT details for randomised controlled trials (see Articles)

8 We encourage disclosure of correspondence from other journals and reviewers, if previously submitted, and we might contact relevant editors of such journals

9 Research in context panel, for all primary research Articles

How to submit your paper

Manuscript submission

Manuscript submission to all Lancet journals is free. Manuscripts should be submitted online via the The Lancet Oncology’s online submission and peer review website (known as EM) at www.editorialmanager.com/thelancetoncology

• Simply log on to EM and follow the onscreen instructions for all submissions

• If you have not used EM before, you will need to register first. In EM, the corresponding author is the person who enters the manuscript details and uploads the submission files

• Inclusion of illustrations (eg, photographs, graphs, diagrams) is a prerequisite for many publication types. Submission of original and editable artwork files is encouraged. Digital photography files should have a resolution of at least 300 dpi and be at least 107 mm wide. Before and after images should be taken with the same intensity, direction, and colour of light

• In almost all cases, if you have a finished manuscript, you should submit it, rather than contacting The Lancet Oncology to enquire whether an unseen manuscript is likely to be accepted

• Unless you have been asked by the Editor to submit by email, you should use the online system for all types of submission, including correspondence

• If you have any technical problems or questions, please contact our dedicated customer support:

For the Americas: +1 888 8347287 (09:00 to 17:00 central standard time)

For Asia and Pacific: +81 3 55615032 (09:30 to 17:30 Japan standard time)

For Europe and rest of the world: +44 1865 843577 (08:30 to 17:00 GMT)

For Chinese-speaking customers: +86 10 85208780 (9:00 to 17:30 China standard time)

For Spanish-speaking customers: +34 932 406176 (09:00 to 17:00 GMT)

For French-speaking customers: +33 171 165608 (09:00 to 17:00 GMT)

• Editorial queries can be sent to the Editor, David Collingridge, at david.collingridge@lancet.com

Covering letter

• You should upload your covering letter at the “Enter Comments” stage of the online submission process

• Use the covering letter to explain why your paper should be published in The Lancet Oncology rather than elsewhere

• It is helpful to indicate what could shorten your paper—the full paper can be reviewed and a shorter version published; a table or figure, details of a DNA sequence, or further references, for example, can be published on our website or made available from the authors

Statements, permissions, and signatures

Authors and contributors

• Designated authors should meet all four criteria for authorship in the ICMJE Recommendations

• All authors, and all contributors (including medical writers and editors), should specify their individual contributions at the end of the manuscript

• We require that more than one author has verified the underlying data. The contributors statement should state who those authors are.

• We encourage collaboration and coauthorship with colleagues in the locations where the research is conducted

• The Lancet Group takes a neutral position with respect to territorial claims in institutional affiliations

• When choosing coauthors, we ask lead authors to be mindful of the benefits of diversity in authorship and to consider inviting coauthors who reflect diversity in every sense, including (but not limited to) background, career-stage, gender, geography, and race

• The Lancet Oncology will not publish any paper unless we have the signatures of all authors

• We suggest you use the author statement form and upload the signed copy with your submission.

• Please include written consent of any cited individual(s) noted in acknowledgments or personal communications

• These forms should only be supplied if your paper is selected for peer review. You will receive instruction from the editorial team when to send these documents

• For author groups of more than 30 members, we encourage use of a collaborator or study group for any additional authors. For this collaborator or study group, if they wish to be indexed to the paper, please provide a separate document with a table of first names and surnames of all members of the group (this is to ensure that PubMed and similar databases encode the names correctly).

Forms and signatures

For Reviews, Personal Views, Comments, and Correspondence, we require you to upload your forms at submission. For original research (Articles), we will request these forms after peer review. The following signed statements are required:

• Authors’ contributions

• Conflicts of interest statements (ICMJE forms)

• Statements of role, if any, of medical writer or editor

• Acknowledgments—written consent of cited individual

• Personal communications—written consent of cited individual

• Use of copyright-protected material—signed permission statements from author and publisher

These statements can be scanned and submitted electronically with your submission. Please note that The Lancet journals will accept hand-signed and electronic (typewritten) signatures.

Declaration of interests

A conflict of interest exists when professional judgement concerning a primary interest (such as patients’ welfare or validity of research) may be influenced by a secondary interest (such as financial gain). Financial relationships are easily identifiable, but conflicts can also occur because of personal relationships or rivalries, academic competition, or intellectual beliefs. A conflict can be actual or potential, and full disclosure to the Editor of all relationships is a requisite. Purposeful failure to disclose conflicts is a form of misconduct and might lead to publication of a correction or even to retraction. All submissions to The Lancet Oncology must include disclosure of all relationships in which there is a potential or actual conflict of interest, even if it not directly relevant to the submitted work. The Editor may use such information as a basis for editorial decisions and will publish all disclosures that authors declare on their conflict of interests form. It is the corresponding author’s responsibility to check that all declarations made by authors on their conflicts of interest form are included at the end of the manuscript. Agreements between authors and study sponsors that interfere with authors’ access to all of a study’s data, or that interfere with their ability to analyse and interpret the data and to prepare and publish manuscripts independently, may represent conflicts of interest, and should be avoided. Authors may be required to provide the journal with any such agreements in confidence.

• At the end of the text, under a subheading “Declaration of interests”, all authors must disclose any financial and personal relationships with other people or organisations, even if it does not directly relate to the submitted work. Examples of financial conflicts include employment, consultancies, stock ownership, honoraria, paid expert testimony, patents or patent applications, and travel grants, all within 3 years of beginning the work submitted. If there are no conflicts of interest, authors should state that none exist

• All authors are required to provide a Conflict of Interest Statement and should complete a standard form, which is available at https://www.thelancet.com/for-authors/forms?section=icmje-coi. The form has been modified by the ICMJE following consultation with authors and editors. Further information is available in a joint ICMJE statement published on July 1, 2010. For more information see Lancet 2009; 374: 1395–96.

• For any Review or Personal View, The Lancet Oncology will not publish the manuscript if an author, within the past 3 years, and with a relevant company or competitor, has any stocks or shares, equity, a contract of employment, or a named position on a company board; or has been asked by any organisation other than The Lancet Oncology to write, be named on, or to submit the paper (see Lancet 2004; 363: 2–3)

• For any Review or Personal View, the use of medical writers is not permitted unless they have been paid and instructed directly by an author, or their institution, and their role is purely technical (eg, editing a first draft for language and grammar). If you are contemplating use of a medical writer, please contact the journal immediately to ensure it complies with our policies Role of the funding source (to be included only with Articles)

• All sources of funding should be declared as an acknowledgment at the end of the text

• At the end of the Methods section, under a subheading “Role of the funding source”, authors must describe the role of the study sponsor(s), if any, in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication

• If there is no Methods section, the role of the funding source should be stated as an acknowledgment. If the funding source had no such involvement, the authors should so state

• All authors should confirm that they had full access to all the data in the study and accept responsibility to submit for publication Role of medical writer or editor

• If a medical writer or editor was involved in the creation of your manuscript, we need a signed statement from the corresponding author to include their name and information about funding of this person

• This information should be added to the Acknowledgments and/or Contributors section

• We require signed statements from any medical writers or editors declaring that they have given permission to be named as an author, as a contributor, or in the Acknowledgments section ICMJE COI form

……

更多详情：

https://www.thelancet.com/lanonc/about